

Hanoi, October 20th, 2026**EXPLANATION OF BUSINESS PERFORMANCE
FOR THE THIRD QUARTER OF 2026**

Respectfully to: - State Securities Commission
- Hanoi Stock Exchange

Pursuant to:

- *Legal Regulations on Information Disclosure in the Securities Market;*
- *The self-prepared financial statements for Q3 2026 of Viet Nam Medicinal Materials Joint Stock Company;*

Viet Nam Medicinal Materials Joint Stock Company (Stock code: DVM) would like to provide an explanation for the profit variance in the Q3/2026 compared to the same period in 2025 as follows:

No.	Content	Q3/2026 (VND)	Q3/2025 (VND)	Difference	
				Value (VND)	%
1	Net revenue	17,463,908,139	330,149,798,379	(312,685,890,240)	(94.71)
2	Profit after tax	(14,327,624,586)	8,077,058,164	(22,404,682,750)	(277.39)

Net revenue in Q3/2026 reached **17,463,908,139 VND**, a decrease of **312,685,890,240 VND** compared to the period of 2025, corresponding to a decrease of 94.71%:

The main reason is that, in Q3/2026, the Company's medicinal materials and modern pharmaceutical business activities faced many difficulties, and the number of orders arising decreased significantly compared to the same period last year. At the same time, in Q3/2025, the Company recorded revenue from a number of high-value

contract and orders, making the revenue in that period high. In Q3/2026, these orders no longer arose or had not been yet implemented, leading to a decrease in revenue.

In addition, the increasing competition in the pharmaceutical market, the fluctuations in customers' consumption demand, and the Company's review and restructuring of its business product portfolio also affected the consumption output during the period.

Due to the sharp decrease in net revenue, the profit after tax in Q3/2026 also decreased correspondingly compared to the same period last year. However, the Company still maintains business operations and continues to implement solutions to expand the market, develop the customers and improve operational efficiency in the upcoming periods.

The above is Vietnam Medicinal Materials Joint Stock Company's explanation regarding the profit fluctuations in the Q3/2026 Financial Statements compared to the same period last year.

Best regards./.

Recipients:

- As above;
- Archived at the office.

GENERAL DIRECTOR



Vu Thanh Trung